Antiallodynic effect of intrathecally administered 5-HT2 agonists in rats with nerve ligation

Citation
H. Obata et al., Antiallodynic effect of intrathecally administered 5-HT2 agonists in rats with nerve ligation, PAIN, 90(1-2), 2001, pp. 173-179
Citations number
57
Categorie Soggetti
Neurology,"Neurosciences & Behavoir
Journal title
PAIN
ISSN journal
03043959 → ACNP
Volume
90
Issue
1-2
Year of publication
2001
Pages
173 - 179
Database
ISI
SICI code
0304-3959(20010201)90:1-2<173:AEOIA5>2.0.ZU;2-3
Abstract
We examined the antiallodynic effect of intrathecally administered serotoni n receptor agonists including 5-HT1A, 5-HT1B, 5-HT2 and 5-HT3 receptor subt ypes in a rat model using spinal nerve ligation at L5 and L6. Administratio n of the 5-HT2 receptor agonist, alpha -methyl-5-hydroxytryptamine maleate (alpha -m-5-HT; 3-100 mug) or (+/-)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminop ropane hydrochloride (DOI; 10-100 mug), showed dose-dependent antiallodynic actions with no associated motor weakness. The antiallodynic action of alp ha -m-5-HT was more potent than that of DOI. The effects of 5-HT2 agonists on tactile allodynia were reversed by intrathecal pretreatment with the sel ective 5-HT2 antagonist ketanserin and with the mixed 5-HT1 and 5-HT2 antag onist methysergide. Neither the mixed 5-HT1A and 5-HT1B antagonist cyanopin dolol nor the selective 5-HT3 antagonist MDL72222 attenuated antiallodynic effects induced by 5-HT2 agonists. In contrast, the selective 5-HT1A agonis t 8-hydroxy-2-(di-n-propylamino)-tetralin hydrobromide (8-OH-DPAT; 1-50 mug ), the 5-HT1B agonist 5-methoxy-3-(1,2,5,6-tetrahydro-4-pyridinil)-1H-indol (RU-24969; 10-100 mug) and the 5-HT3 agonist 2-methyl-5-hydroxytryptamine maleate (2-m-5-HT; 30-300 mug) all lacked significant antiallodynic action with intrathecal administration. These results indicate that the 5-HT2 rece ptor plays an essential role in spinal suppression of neuropathic pain by 5 -HT. (C) 2001 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights reserved.